SCHEMBL5792889

SCHEMBL5792889

CCCC(N)c1ccccc1N1CCCCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 1/20 0.46
▸ KCNQ2 O43526 5/20 0.43
▸ GAA P10253 2/20 0.42
▸ MAPK1 P28482 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ MC4R P32245 5/20 0.40
▸ ALDH1A1 P00352 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ NCF1 P14598 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ KCNQ3 O43525 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ KCNE1 P15382 1/20 0.36
▸ KCNQ1 P51787 1/20 0.36
▸ KCNQ4 P56696 1/20 0.36
▸ POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2339105 1.00 KEAP1 (0.46) KEAP1KCNQ2GAAMAPK1NPC1
SCHEMBL7897470 1.00 KEAP1 (0.46) KEAP1KCNQ2GAAMAPK1NPC1
Hydrochloric Acid SCHEMBL10638555 0.98 KEAP1 (0.45) KEAP1KCNQ2GAAMAPK1NPC1
SCHEMBL7896588 0.98 KCNQ2 (0.44) KEAP1KCNQ2GAAMAPK1NPC1
SCHEMBL5792763 0.91 KEAP1 (0.44) KEAP1KCNQ2GAAMAPK1NPC1
Hydrochloric Acid SCHEMBL17871814 0.90 KEAP1 (0.42) KEAP1KCNQ2GAAMAPK1NPC1
SCHEMBL7900199 0.90 KEAP1 (0.42) KEAP1KCNQ2GAAMAPK1NPC1
SCHEMBL5794047 0.88 LMNA (0.42) KEAP1KCNQ2GAAMAPK1NPC1
SCHEMBL19665213 0.86 KEAP1 (0.45) KEAP1KCNQ2GAAMAPK1NPC1
Hydrochloric Acid SCHEMBL17872072 0.85 KEAP1 (0.44) KEAP1KCNQ2GAAMAPK1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060079696-A1 Substituted compounds derived from N-(benzyl)phenylacetamide, preparation and uses GENFIT (FR) 2006-04-13 — — US disclosed
WO-2006035157-A2 SUBSTITUTED N-(BENZYL)PHENYLACETAMIDE DERIVATIVE COMPOUNDS, PREPARATION METHOD THEREOF AND USES OF SAME AS PPAR LIGANDS IN THE TREATMENT OF LIPID AND/OR GLUCIDIC DISORDERS GENFIT (FR) 2006-04-06 — — WO disclosed
EP-0779284-B1 Novel 2-naphthamide derivatives and their use in therapy as D3 receptor agonists INST NAT SANTE RECH MED (FR) 2002-07-10 — — EP disclosed
US-RE37035-E1 HYPOGLYCEMIC AGENTS BOEHRINGER INGELHEIM KG (DE) 2001-01-30 — — US disclosed
US-6143769-A ENANTIOMORPH KARL THOMAE GMBH (DE) 2000-11-07 — — US disclosed
US-5985895-A 2-naphthamide derivatives and their therapeutic applications INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE-INSERM (FR) 1999-11-16 — — US disclosed
US-5872119-A 2-Naphthamide derivatives and their therapeutic applications Institut National De La Sante et De La Recherche Medicale--INSERM (FR) 1999-02-16 — — US disclosed
EP-0779284-A1 Novel 2-naphthamide derivatives and their use in therapy as D3 receptor agonists INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1997-06-18 — — EP disclosed
US-5312924-A Compounds for lowering blood sugar and effecting metabolism DR. KARL THOMAE GMBH (DE) 1994-05-17 — — US disclosed
US-5216167-A Hypoglycemic agents DR. KARL THOMAE GMBH (DE) 1993-06-01 — — US disclosed
EP-0147850-B1 PHENYLACETIC-ACID DERIVATIVES, MEDICINES CONTAINING THESE COMPOUNDS AND PROCESS FOR THEIR PREPARATION Dr. Karl Thomae GmbH (DE) 1989-06-14 — — EP disclosed
US-4735959-A HYPOGLYCEMIC AGENTS DR. KARL THOMAE GMBH (DE) 1988-04-05 — — US disclosed
EP-0099017-B1 PHENYL-ACETIC-ACID DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSTIONS CONTAINING THEM Dr. Karl Thomae GmbH (DE) 1988-03-02 — — EP disclosed
EP-0147850-A2 Phenylacetic-acid derivatives, medicines containing these compounds and process for their preparation Dr. Karl Thomae GmbH (DE) 1985-07-10 — — EP disclosed
EP-0099017-A2 Phenyl-acetic-acid derivatives, their preparation and pharmaceutical compostions containing them Dr. Karl Thomae GmbH (DE) 1984-01-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079696-A1 Substituted compounds derived from N-(benzyl)phenylacetamide, preparation and uses AADAC, NAT1, PARN KEAP1 714/4885KCNQ2 1084/4885GAA 433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback